Biomy Inc. announced membership at Johnson & Johnson Innovation – JLABS in Singapore
at Johnson & Johnson Innovation – JLABS in Singapore 株式会社biomyはJLABS @
Singaporeへの参画を通して腫瘍微小環境の解析を通じて新たな価値を提供していきます Biomy Inc. has joined Johnson &
Johnson Innovation – JLABS in Singapore, becoming part of the world’s largest
network of open innovation ecosystems, effective April 1, 2024. Tokyo, Japan,
2024 – Biomy Inc. announced today that, effective 1st April, 2024, it has become
a member of Johnson & Johnson Innovation – JLABS in Singapore (‘JLABS’). JLABS
is the largest global network of open innovation ecosystems, enabling and
empowering emerging companies with the knowledge, experience, partnerships, and
venture connections across the spectrum of healthcare, including the
pharmaceutical and medical technology sector. The company is working toward
precision medicine through AI pathological analysis. The company will expand its
business to the Southeast Asia area through incubation with JLABS in Singapore.
“Biomy is dedicated to advancing precision medicine through the AI analysis of
pathology images. We have a particular strength in analyzing the tumor
microenvironment. Additionally, we are developing a platform that enables
combined analysis of spatial transcriptome data and pathology image AI. We are
very excited to be a JLABS company in Singapore and look forward to delivering
new value through the analysis of the tumor microenvironment." – Teppei Konishi,
CEO
About Biomy Inc.
BIOMY, Inc. aims to realize personalized medicine by making full use of
pathology AI analysis. With the recent progress of cancer immunotherapy and
molecular targeted therapy, it has become clear that the “cancer
microenvironment (TME)" that constitutes the tumor surroundings is important for
drug efficacy and patient prognosis. In particular, we focus on the spatial
information of the various immune cells that make up the TME for each patient.
However, the TME contains tens to hundreds of thousands of cells spread across
the TME, and identifying these cells and quantifying and interpreting their
spatial information is difficult in daily medical practice. BIOMY is developing
technologies to solve these problems by utilizing its proprietary pathology
image AI technology and is conducting research to establish new validity indices
and patient stratification. We are also developing analysis technologies that
combine pathology images and spatial transcriptomes.
About DeepPathFinder(TM)
DeepPathFinder(TM) is a research-oriented service that helps improve our
understanding of cancer cells and the cancer immune microenvironment surrounding
them. The AI implemented in DeepPathFinder(TM) detects not only epithelial
cells, lymphocytes, and macrophages but also fibroblasts and plasma cells. It
also assists in the detailed classification of tissue, such as tumor, necrosis,
and stroma. Combining this information, the number and density of lymphocytes
and fibroblasts in the stroma can be quantitatively evaluated to determine the
number of immune cells present at a specific distance from the tumor. In
addition, the ability to detect specific features of some driver gene mutations
based on morphological characteristics has been implemented. It is also possible
to combine spatial transcriptome data with pathology images for analysis.
*DeepPathFinder(TM) is for research use only
Examples of DeepPathFinder(TM) analysis (top left: original H&E image, top
right: tissue area detection, bottom left: cell detection, bottom right:
analysis of cell-cell interaction by graph network)
For more information, please visit
Media Contact
Company Website: https://www.biomy-tech.com/
Adress: 3-8-3 Nihonbashihoncho, Chuo City, Tokyo 103-0023
Email: [email protected]